This suggests that advancements in our understanding of the blood-tumor barrier and the ability of certain therapeutic agents to reach the brain may contribute to improved management and outcomes for individuals facing HER2-positive breast cancer with brain involvement. Here, ERBB2 is linked to breast carcinoma.